Rafa Laboratories
Prescription and Over-the-Counter Medicines
Startup Acquired Health Tech & Life Sciences Est. 1937 Acquired
Total Raised
Undisclosed
Acquired
Last Round
Undisclosed
Team
4
51-200 employees
Confidence
90/100
News
8
articles
Patents
1
About
Rafa Laboratories is a pharmaceutical company that markets, manufactures, and distributes consumer health products and prescription and over-the-counter medicines, mainly proprietary formulations as well as generic formulations. The company manufactures a wide variety of medications based on in-house development and through external agreements. Rafa Laboratories is also involved in marketing drugs produced by international corporations such as Dr. Falk Pharma, Helsinn Healthcare, Boehringer Ingelheim, Purdue Pharma, 3M Healthcare, United Therapeutics, and Mundipharma. Rafa Laboratories received FDA approval for their 10 mg midazolam autoinjector, which can treat seizures caused by nerve agent exposure.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
Biologicals
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business Model
B2B
Tags
pharma-companiesdrug-designdrug-discoveryhealthcarepharmaceuticalsmanufacturingmarketinglaboratoriesbiotechnology
Funding & Events
Oct 2020
Exit Undisclosed
News (8)
Jun 23, 2024 · www.themarker.com
growth-positive
שווי של 1.2 מיליארד שקל: פימי במגעים למכירת 10%–15% מרפא
Investment
Aug 29, 2022 · www.prnewswire.com
growth-positive
Rafa Receives FDA Approval For Life-saving Midazolam Autoinjector
PartnersCustomers
Aug 1, 2022 · www.prnewswire.com
growth-positive
Rafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in medicines addressing rare diseases
PartnersInvestmentExpand
Oct 28, 2020 · en.globes.co.il
growth-negative
FIMI buys Rafa from Sackler family at NIS 700m valuation
Acquisition
Oct 8, 2020 · en.globes.co.il
growth-negative
Sackler family in talks to sell control of Rafa to FIMI
Acquisition
May 1, 2019 · www.newswire.ca
growth-positive
Panaxia and Rafa sign a collaboration agreement with PlantEXT to research and manufacture the first medical cannabis suppositories intended for patients suffering from inflammatory bowel disease ("IBD", Crohn's and colitis)
Partners
Jul 24, 2018 · www.businesswire.com
Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medical Countermeasure for Chemical Nerve Agents
Apr 26, 2017 · www.livescience.com
growth-positive
Nerve Gas Attack: New Treatment Cleared, But More Drugs Are Needed
Customers
Details
Product Stage
Released
Employees
51-200
Exact Count
143
District
Jerusalem District
Founded
1937
Registrar
511033789
Crunchbase
rafa-laboratories-ltd
Locations
Shlomo Momo ha-Levi St 5, Jerusalem, Israel
Links
Website
LinkedIn
Careers
Admin
Last Update
Nov 18, 2024
Verified by
Yanina Wainscheinker
Missing
video or image, markets, not claimed
Team (4)
Amir Levin
CEO & Chairman
Iddo Leshem
CEO
Goozy Hartog
VP of Business Development
Liraz Levi
HR Director
Internal
Created by
Sharon Shapira (shapira.sharon2@gmail.com)
Created
2014-11-09T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)
Status
Acquired by FIMI Opportunity Funds on Oct, 2020